← Back to patent-cliff list
CAS 2675521-16-9
Methyl 4-[4-[(tert-butoxycarbonyl)amino]-6-methylpyrimidin-2-yl]-1-methoxycyclohexane-1-carboxylate
Codes：(IV)1024528-2-a
Application context (from source-drug indications)
非小细胞肺癌普拉替尼甲状腺瘤普拉替尼甲状腺髓样癌普拉替尼
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 普拉替尼Pralsetinib | Tier C — Watch / trade | 2031 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-Chloro-6-methylpyrimidin-4-amine→tert-Butyl (2-chloro-6-methylpyrimidin-4-yl)carbamate→Methyl 4-iodo-1-methoxycyclohexane-1-carboxylate→Methyl 4-[4-[(tert-butoxycarbonyl)amino]-6-methylpyrimidin-2-yl]-1-methoxycyclohexane-1-carboxylate→Methyl 1-methoxy-4-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)cyclohexane-1-carboxylate→3-Amino-1-Boc-5-methyl-1H-pyrazole→Methyl 1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxylate→(1S)-1-[6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethan-1-amine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.